$51.43 Million in Sales Expected for Vanda Pharmaceuticals Inc. (VNDA) This Quarter

Brokerages forecast that Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) will report $51.43 million in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Vanda Pharmaceuticals’ earnings, with the highest sales estimate coming in at $53.00 million and the lowest estimate coming in at $49.70 million. Vanda Pharmaceuticals reported sales of $44.28 million in the same quarter last year, which would suggest a positive year over year growth rate of 16.1%. The company is scheduled to report its next earnings results on Wednesday, February 13th.

According to Zacks, analysts expect that Vanda Pharmaceuticals will report full-year sales of $191.47 million for the current year, with estimates ranging from $189.70 million to $193.00 million. For the next year, analysts expect that the company will post sales of $248.30 million, with estimates ranging from $229.00 million to $277.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research analysts that follow Vanda Pharmaceuticals.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its earnings results on Wednesday, November 7th. The biopharmaceutical company reported $0.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.18. Vanda Pharmaceuticals had a return on equity of 5.88% and a net margin of 7.06%. The business had revenue of $49.13 million during the quarter, compared to analyst estimates of $49.44 million. During the same quarter last year, the firm earned ($0.03) earnings per share. The company’s revenue for the quarter was up 18.9% compared to the same quarter last year.

VNDA has been the subject of a number of recent research reports. Cantor Fitzgerald reiterated a “hold” rating and issued a $26.00 target price on shares of Vanda Pharmaceuticals in a research note on Wednesday, October 3rd. Oppenheimer set a $29.00 target price on Vanda Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, November 8th. Stifel Nicolaus set a $31.00 target price on Vanda Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, November 8th. Citigroup increased their target price on Vanda Pharmaceuticals from $27.00 to $31.00 and gave the company a “buy” rating in a research note on Tuesday, October 16th. Finally, Zacks Investment Research upgraded Vanda Pharmaceuticals from a “hold” rating to a “buy” rating and set a $26.00 target price for the company in a research note on Friday, October 12th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the company’s stock. Vanda Pharmaceuticals presently has an average rating of “Buy” and an average target price of $28.43.

Hedge funds and other institutional investors have recently modified their holdings of the business. United Services Automobile Association acquired a new stake in Vanda Pharmaceuticals during the 3rd quarter valued at approximately $211,000. Trexquant Investment LP acquired a new stake in Vanda Pharmaceuticals during the 2nd quarter valued at approximately $212,000. Hartford Investment Management Co. acquired a new stake in Vanda Pharmaceuticals during the 2nd quarter valued at approximately $214,000. Meeder Asset Management Inc. grew its stake in Vanda Pharmaceuticals by 164.6% during the 3rd quarter. Meeder Asset Management Inc. now owns 11,417 shares of the biopharmaceutical company’s stock valued at $261,000 after purchasing an additional 7,102 shares in the last quarter. Finally, NumerixS Investment Technologies Inc grew its stake in Vanda Pharmaceuticals by 92.9% during the 2nd quarter. NumerixS Investment Technologies Inc now owns 11,835 shares of the biopharmaceutical company’s stock valued at $227,000 after purchasing an additional 5,700 shares in the last quarter.

VNDA stock opened at $25.04 on Monday. Vanda Pharmaceuticals has a 1 year low of $13.10 and a 1 year high of $25.48. The stock has a market capitalization of $1.31 billion, a PE ratio of -71.54, a P/E/G ratio of 3.41 and a beta of 1.06.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.

Recommended Story: What is Compound Interest?

Get a free copy of the Zacks research report on Vanda Pharmaceuticals (VNDA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply